FSS, Samsung Bio-Logics special supervision undertaken ... Shares fall

[Goyounghun financial newspaper reporter Korea] decided to embark on the Financial Supervisory Service Special Supervision for Samsung Bio-Logics is accounting fraud controversy had one. This morning on the 30th, Samsung Bio-Logics price has shown a downward trend compared to the previous day.

Financial authorities have reportedly discussed the Samsung Bio-Logics supervision issues in the FSC held the day before the Securities and Futures Commission and thus decides.

The FSS said that the suspect parts, etc. After reviewing the audit report by South Korea's Samsung Bio-Logics supervision of Certified Public Accountants have decided to launch special supervision to ensure this.

Samsung Bio-Logics is a pharmaceutical manufacturer that Cheil Industries and Samsung C & T merger retain the majority stake. In November, Samsung Bio-Logics traded month, found a continued deficit since its establishment in 2011. But the Samsung bio subsidiaries in 2015, the move to fair value upon the corporate value of the book value of the piece obtained a net profit of 1.9 trillion won expedient accounting suspicions were raised.

In addition, the Korea Exchange too high if it is determined that future growth even deficit in 2016 was enterprise days to change preference doubt controversial provisions to enable the public. People's Solidarity for Participatory Democracy is a value-priced five trillion pieces of Samsung bio that out after four years operating losses recently established thing, saying the problem had sent a questionnaire to the FSS.

Jin Ungseop Chapter FSS is also a bar chair larger debate on this issue in the past Affairs Committee work report said that "we will decide in consultation with the relevant agencies."



Daily Economic News Finance FNTIMES - commercial reprint, copy, distribute prohibited purposes under the Copyright Act
Copyright ⓒ Korea's Financial News & FNTIMES.com